Jump to:

Cardiac Risk Calculator

Cardiac Risk Calculator

Choose the matching data for each criteria

People with absolute risk of ≥ 20% should be considered for treatment:

  • with a statin to achieve a Total Cholesterol <5 and/or LDL cholesterol <3.2
  • with anti-hypertensives to achieve a BP ≤ 160/90 (ideally ≤ 140/80).

Categorisation of 10 year Risk of CHD Event:

  • Very Low risk: < 10%
  • Low risk: < 15%
  • Moderate risk: 15-20%
  • High risk: > 20%

† if HDL unknown, assume 1.1 in Males, 1.4 in Females

* CHD Event: Coronary Death, Myocardial Infarction, Angina.

** 'Ideal' risk represents:

  • Total Cholesterol = 4.1 - 5.1
  • HDL = 1.2 (Male), 1.4(Female)
  • BP < 120/80
  • No Diabetes, Non Smoker

This risk assessment only applies to assessment for Primary Prevention of CHD, in people who do not have evidence of established vascular disease.

Patients who already have evidence of vascular disease usually have a >20% risk of further events of over 10 years, and require vigorous Secondary Prevention.

People with a Family History of premature vascular disease are at higher risk than predicted; Southern Europeans and some Asians may have a lower risk in relation to standard risk factors.

The MIMS cardiac risk calculator is based on data from the Framingham study published in Circulation in 1998.1

The National Institute for Health and Clinical Excellence (NICE) Guideline on the Management of Hypertension in Adults in Primary Care, updated in 2006,2 recommends that cardiovascular risk is estimated according to the Joint British Societies CVD risk assessment programme/risk charts. These are available on the BHS web site at http://www.bhsoc.org/.

References
1. Prediction of coronary heart disease using risk factor categories. Wilson PWF, et al. Circulation (1998;97;1837-47).
2. Hypertension: Management of hypertension in adults in primary care. NICE Clinical Guideline 34 (June 2006) (partial update of NICE Clinical Guideline 18). http://www.nice.org.uk

Latest Guidelines

Topotecan for the Treatment of Relapsed Small-Cell Lung Cancer

Technology Appraisal Guidance No. 184 Source: National Institute for Health and Clinical...

Topotecan for the Treatment of Recurrent and Stage IVB Cervical Cancer

Technology Appraisal Guidance No. 183 Source: National Institute for Health and Clinical...

Prasugrel for the Treatment of Acute Coronary Syndromes with Percutaneous Coronary Intervention

Technology Appraisal Guidance No. 182 Source: National Institute for Health and Clinical...

Lenalidomide for the Treatment of Multiple Myeloma in People who have Received at Least One Prior Therapy

Technology Appraisal Guidance No. 171 Source: National Institute for Health and Clinical...

Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck

Technology Appraisal Guidance No. 172 Source: National Institute for Health and Clinical...

 

GP Curriculum Centre

Educational resource for the learning and teaching of the
GP curriculum

Click here to read more

Deleted products

Cumulative list of products discontinued from the UK market
in 2010

Click here to read more

Treating psoriasis

Healthcare Republic resource centre for diagnosing and managing psoriasis

Click here to read more

MIMs Drug Search

Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.

Find drugs by:

NICE Guidance: Lipid Modification

NICE Lipid Modification

MIMS Summary of
NICE guideline

Comparison table: contraceptives

Contraceptives Table

Combined, phasic and progestogen-only preparations

 

Back to top